{"changes":[],"country":"IE","description":"SynOx Therapeutics is developing emactuzumab, a monoclonal antibody against CSF-1R, to shut down macrophage-driven disease activity. It targets patients with tenosynovial giant cell tumor and other macrophage-driven rare diseases where treatment options are thin. Focusing all R&D on one antibody builds deeper macrophage-biology expertise than a broad pipeline allows.","domain":"synoxtherapeutics.com","employees":null,"founded":2020,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"biotech|oncology|therapeutics","investors":[],"lat":53.349379,"lng":-6.260559,"location":"Dublin Ireland","name":"SynOx Therapeutics","rounds":[{"amountQuarantined":false,"amountUsd":75000000,"currency":"USD","date":"2024-04-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"synoxtherapeutics-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},{"fact":"existence","publisher":"synoxtherapeutics.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://synoxtherapeutics.com"},{"fact":"description","publisher":"synoxtherapeutics.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://synoxtherapeutics.com"}],"stage":"series-b+","techStack":["Cloudflare","reCAPTCHA","Slick 1.8.1","jQuery CDN","jQuery Migrate 3.4.1","PHP","cdnjs","Contact Form 7 6.1.6","Cookiebot","Vercel Speed Insights","Onsen UI","WordPress"],"totalRaisedUsd":75000000,"updatedAt":"2026-05-07"}